Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 37Observational 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 1

Interventions

Sunitinib 16exemestane 11Afatinib 11palbociclib 10Rituximab 10Bevacizumab 10Erlotinib Hydrochloride 9Leuprolide 8Radiotherapy 7Drug Therapy 7Axitinib 7avelumab 6Letrozole 6Capecitabine 6Blood Specimen Collection 6enzalutamide 5Trastuzumab 5Surveys and Questionnaires 5Standard of Care 5Docetaxel 5Aromatase Inhibitors 5lorlatinib 4Specimen Handling 4Radiation 4Mammography 4Crizotinib 4Anastrozole 4Abiraterone Acetate 4temsirolimus 3talazoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Has results × talazoparib × Clear all
NCT05141708 2024-02-16

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Pfizer

Completed
33 enrolled 9 charts
Breast

Breast Neoplasms

NCT04987931 2024-01-22

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Pfizer

Completed
84 enrolled 11 charts
Breast

Breast Neoplasms

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡